Our firm boasts IP law’s largest and most experienced biotechnology group, with more than 60 attorneys and scientists representing clients in all stages of their business and technology development.
Our clients are innovators in a variety of disciplines including PCR, molecular tools and probes, immunology (antibodies and other binding proteins), cell varieties and uses (including stem cells) and biological polymers, to name but a few.
Our expertise across the entire biotech landscape gives us great insight into specific technologies, systems and markets. More importantly, our holistic understanding of the interrelated technologies and systems typically involved in a single invention allows us to provide coordinated guidance and counsel from inception though introduction.
Working in collaboration with more than 300 IP firms worldwide, we effect patent, trademark, copyright, and other filings, and direct oppositions, cancellations, and litigation matters in over 120 countries. We have considerable experience in negotiating and drafting traditional licensing agreements as well as agreements for strategic alliances, partnerships and joint ventures.
We also maintain a talented litigation department adept in all aspects of biotechnology IP law, including the Biosimilars legislation. Our extensive Hatch-Waxman litigation experience combined with our understanding of the biotechnology industry uniquely positions Knobbe Martens to help clients develop and implement litigation strategies designed to maximize their place in the Biosimilars market place. In addition, we have considerable experience litigating before the U.S. Court of Appeals for the Federal Circuit and the International Trade Commission.
Our attorneys have experience in all areas of Biotechnology, including: